Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 14;9(9):2970.
doi: 10.3390/jcm9092970.

Lessons from the CONSCIOUS-1 Study

Alexander J Schupper  1 , Matthew E Eagles  2 , Sean N Neifert  1 , J Mocco  1 , R Loch Macdonald  3
Affiliations
Review

Lessons from the CONSCIOUS-1 Study

Alexander J Schupper et al. J Clin Med. .

Abstract

After years of research on treatment of aneurysmal subarachnoid hemorrhage (aSAH), including randomized clinical trials, few treatments have been shown to be efficacious. Nevertheless, reductions in morbidity and mortality have occurred over the last decades. Reasons for the improved outcomes remain unclear. One randomized clinical trial that has been examined in detail with these questions in mind is Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1). This was a phase-2 trial testing the effect of clazosentan on angiographic vasospasm (aVSP) in patients with aSAH. Clazosentan decreased moderate to severe aVSP. There was no statistically significant effect on the extended Glasgow outcome score (GOS), although the study was not powered for this endpoint. Data from the approximately 400 patients in the study were detailed, rigorously collected and documented and were generously made available to one investigator. Post-hoc analyses were conducted which have expanded our knowledge of the management of aSAH. We review those analyses here.

Keywords: angiographic vasospasm; cerebral aneurysm; cerebral infarction; delayed cerebral ischemia; management; subarachnoid hemorrhage.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Macdonald R.L., Schweizer T.A. Spontaneous subarachnoid haemorrhage. Lancet. 2017;389:655–666. doi: 10.1016/S0140-6736(16)30668-7. - DOI - PubMed
    1. Maher M., Schweizer T.A., Macdonald R.L. Treatment of spontaneous subarachnoid hemorrhage: Guidelines and gaps. Stroke. 2020;51:1326–1332. doi: 10.1161/STROKEAHA.119.025997. - DOI - PubMed
    1. Choi H.A., Ko S.B., Chen H. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit. Care. 2012;16:363–367. doi: 10.1007/s12028-012-9670-8. - DOI - PubMed
    1. Molyneux A.J., Kerr R.S.C., Yu L.-M., Clarke M., Sneade M., Yarnold J.A., Sandercock P., International subarachnoid aneurysm trial (ISAT) collaborative group International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366:809–817. doi: 10.1016/S0140-6736(05)67214-5. - DOI - PubMed
    1. Dorhout Mees S.M., Rinkel G.J.E., Feigin V.L., Algra A., van den Bergh W.M., Vermeulen M., van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst. Rev. 2007:CD000277. doi: 10.1002/14651858.CD000277.pub3. No. 3. - DOI - PMC - PubMed

LinkOut - more resources